Nabriva Therapeutics Plc
NASDAQ:NBRV 11:31:26 AM EDT
Earnings Announcements
Nabriva Therapeutics Reports Fourth Quarter Revenue Of $9.3 Mln
Published: 03/29/2022 20:30 GMT
Nabriva Therapeutics Plc (NBRV) - Nabriva Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update.
Q4 Revenue $9.3 Million.
Cash Runway Extended Well Into Q4 2022.
Qtrly Loss per Share Basic and Diluted $0.24.
Q4 Revenue $9.3 Million.
Cash Runway Extended Well Into Q4 2022.
Qtrly Loss per Share Basic and Diluted $0.24.
Revenue is expected to be $9.47 Million
Adjusted EPS is expected to be -$0.19
Next Quarter Revenue Guidance is expected to be $11.05 Million
Next Quarter EPS Guidance is expected to be -$0.18
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.19
Next Quarter Revenue Guidance is expected to be $11.05 Million
Next Quarter EPS Guidance is expected to be -$0.18
More details on our Analysts Page.